LOS ANGELES, May 06, 2026--Surf Air Mobility Inc. (NYSE: SRFM) ("Surf Air Mobility", or the "Company") today provided details on the commercial go-to-market strategy for SurfOS, the Company’s AI-enabled software operating system powered by Palantir Technologies ("Palantir"). SurfOS’s products serve the fragmented Part 135 private aviation and air mobility market through BrokerOS, OperatorOS, and S...
LOS ANGELES, May 06, 2026--Surf Air Mobility Inc. (NYSE: SRFM) ("Surf Air Mobility", or the "Company") today provided details on the commercial go-to-market strategy for SurfOS, the Company’s AI-enabled software operating system powered by Palantir Technologies ("Palantir"). SurfOS’s products serve the fragmented Part 135 private aviation and air mobility market through BrokerOS, OperatorOS, and SurfOS Enterprise Solutions, each monetized through distinct revenue models for brokers, operators, a
Novo Nordisk Soars After New Obesity Pill Momentum Lifts Guidance Novo Nordisk shares jumped as much as 9% in Copenhagen, suggesting the stock may finally be bottoming out after a vicious multi-year bear market. The move followed the Danish drugmaker's decision to raise its 2026 guidance ranges for adjusted sales and adjusted operating profit, citing solid momentum in Wegovy sales. Novo now expect...
Novo Nordisk Soars After New Obesity Pill Momentum Lifts Guidance Novo Nordisk shares jumped as much as 9% in Copenhagen, suggesting the stock may finally be bottoming out after a vicious multi-year bear market. The move followed the Danish drugmaker's decision to raise its 2026 guidance ranges for adjusted sales and adjusted operating profit, citing solid momentum in Wegovy sales. Novo now expects full-year sales and profit declines of around 12%, down from a previous forecast of around 13%. The upgraded outlook was "driven by increased expectations for GLP-1 product sales," according to the company. Here's a snapshot of the new full-year forecast, courtesy of Bloomberg: Sees adjusted change in sales at constant exchange rates -4% to -12%, saw -5% to -13%, estimate -7.63% (Bloomberg Consensus) Sees adjusted change in operating profit at constant FX -4% to -12%, saw -5% to -13%, estimate -8.26% The key bright spot was momentum in the Wegovy pill: Wegovy pill was launched in the US on 5 January 2026, and for the week ending 17 April, total weekly prescriptions exceeded 200,000. Coupled with total prescriptions for Q1 2026 of around 1.3 million and now more than 2 million since launch, it marks the strongest-ever GLP-1 volume launch in the US. Q1 2026 sales for the Wegovy pill reached DKK 2,256 million, impacted by pre-launch pipeline fill with wholesalers and telehealth partners. Pending regulatory decisions, the first Wegovy pill launches outside the US are expected during the second half of 2026. "We have seen more than 1 million people using the Wegovy pill," CEO Mike Doustdar told analysts on an earnings call earlier. He noted that patients are switching from competing products, with "limited cannibalization" of Novo's other drugs. Still, Novo's overall business remains under pressure. First-quarter sales fell 10% to 70.1 billion Danish kroner, while adjusted operating profit dropped 15%. Diabetes drug sales fell 18%, with Ozempic hitting its lowest level in two ...
Timken press release ( TKR ): Q1 Non-GAAP EPS of $1.67 beats by $0.17 . Revenue of $1.23B (+7.9% Y/Y) beats by $70M . Sales of $1.23 billion, up 8 percent from last year First-quarter diluted EPS of $1.40; adjusted EPS of $1.67 Net income margin of 8.0 percent; adjusted EBITDA margin of 18.8 percent Raises 2026 outlook; now expects 2026 EPS of $4.70-$5.20, with adjusted EPS of $5.75-$6.25 (vs. con...
Timken press release ( TKR ): Q1 Non-GAAP EPS of $1.67 beats by $0.17 . Revenue of $1.23B (+7.9% Y/Y) beats by $70M . Sales of $1.23 billion, up 8 percent from last year First-quarter diluted EPS of $1.40; adjusted EPS of $1.67 Net income margin of 8.0 percent; adjusted EBITDA margin of 18.8 percent Raises 2026 outlook; now expects 2026 EPS of $4.70-$5.20, with adjusted EPS of $5.75-$6.25 (vs. consensus of $5.88) More on Timken The Timken Company: On A Roll And Reasonably Valued The Timken Company (TKR) Presents at 18th Annual Evercore Industrial Conference - Slideshow The Timken Company (TKR) Presents at Citi's Global Industrial Tech & Mobility Conference 2026 Transcript Timken Q1 2026 Earnings Preview Small- and mid-cap industrials enter ‘next wave’ for rebalancing: J.P. Morgan
Vermilion Energy press release ( VET ): Q1 GAAP EPS of -C$0.92. Generated C$232 million (C$1.52/basic share) of fund flows from operations ("FFO") and $98 million of free cash flow ("FCF"), fully fundingC$135 million of exploration and development ("E&D") capital expenditures while strengthening the balance sheet and returning cash toshareholders. More on Vermilion Energy Inc. Vermilion Energy Inc...
Vermilion Energy press release ( VET ): Q1 GAAP EPS of -C$0.92. Generated C$232 million (C$1.52/basic share) of fund flows from operations ("FFO") and $98 million of free cash flow ("FCF"), fully fundingC$135 million of exploration and development ("E&D") capital expenditures while strengthening the balance sheet and returning cash toshareholders. More on Vermilion Energy Inc. Vermilion Energy Inc. 2025 Q4 - Results - Earnings Call Presentation Vermilion Well-Positioned For European Natural Gas Price Spike Vermilion Energy: A Deep Value Natural Gas Play That's Still Too Cheap Vermilion reports strong Q1 output, expands Germany footprint, exits Croatia asset Best performing energy foreign stocks YTD
Due to many obstacles – from security to air fares – local fans lose out as African artists tour overseas instead. But as western corporations invest, there are more worries besides When a major African pop artist announces a world tour these days, you will see Paris, New York, Toronto and Amsterdam among the dates. You will see multiple nights at London’s O2 Arena – a venue that has become a regu...
Due to many obstacles – from security to air fares – local fans lose out as African artists tour overseas instead. But as western corporations invest, there are more worries besides When a major African pop artist announces a world tour these days, you will see Paris, New York, Toronto and Amsterdam among the dates. You will see multiple nights at London’s O2 Arena – a venue that has become a regular hub for Nigerian pop supremacy. You will see grand, multimillion-dollar stage designs, towering LED screens and meticulously choreographed dancing as artists such as Burna Boy, Wizkid, Asake, Rema, Tyla and Tems have become global stars. What you will rarely see, however, is a comprehensive, interconnected list of dates in Accra, Nairobi, Johannesburg, Kigali or Luanda: the cities that birthed these acts. It is a central paradox of the current African music surge: the continent’s biggest cultural exports are struggling to perform consistently for audiences across the continent. Continue reading...
Investing.com -- SpaceX is proposing to invest $55 billion to build a semiconductor production facility in Texas, according to a Bloomberg report that cites a public notice posted on the Grimes County website Wednesday.
Investing.com -- SpaceX is proposing to invest $55 billion to build a semiconductor production facility in Texas, according to a Bloomberg report that cites a public notice posted on the Grimes County website Wednesday.